Inotuzumab Ozogamicin

Immunotoxin that consists of anti-CD22 (CD22 ANTIGEN) humanized monoclonal antibody covalently linked to the antineoplastic antibiotic CALICHEAMICIN. It is used for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (LEUKEMIA, ACUTE LYMPHOBLASTIC).

Also Known As:

Networked: 187 relevant articles (28 outcomes, 48 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Vandendries, Erik: 25 articles (01/2022 - 04/2010)
2.	Jabbour, Elias: 22 articles (01/2022 - 08/2013)
3.	Kantarjian, Hagop: 18 articles (01/2022 - 06/2013)
4.	Kantarjian, Hagop M: 18 articles (01/2022 - 08/2016)
5.	Stelljes, Matthias: 17 articles (01/2022 - 08/2016)
6.	O'Brien, Susan: 17 articles (01/2021 - 06/2013)
7.	Advani, Anjali S: 15 articles (01/2022 - 04/2014)
8.	DeAngelo, Daniel J: 15 articles (01/2022 - 08/2016)
9.	Stock, Wendy: 13 articles (08/2022 - 08/2016)
10.	Wang, Tao: 11 articles (01/2022 - 08/2016)

Related Diseases

1.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/15/2018 - "Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia." 10/25/2023 - "Phase II Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia in Remission." 01/01/2022 - "Children's Oncology Group trial AALL1621 was conducted to prospectively determine the safety and efficacy of inotuzumab ozogamicin (InO) in pediatric and adolescent patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). " 01/01/2018 - "Inotuzumab ozogamicin (InO) has demonstrated efficacy and tolerability in patients aged 18 to 78 years with relapsed/refractory acute lymphoblastic leukemia (ALL) in the INO-VATE trial. " 01/01/2021 - "Inotuzumab ozogamicin (INO) showed improved treatment outcomes for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) but can induce hepatotoxic adverse events. "
2.	Residual Neoplasm 08/25/2016 - "Among the patients who had complete remission, a higher percentage in the inotuzumab ozogamicin group had results below the threshold for minimal residual disease (0.01% marrow blasts) (78.4% vs. 28.1%, P<0.001); the duration of remission was longer in the inotuzumab ozogamicin group (median, 4.6 months [95% CI, 3.9 to 5.4] vs. 3.1 months [95% CI, 1.4 to 4.9]; hazard ratio, 0.55 [95% CI, 0.31 to 0.96]; P=0.03). " 01/01/2022 - "Minimal residual disease-negative complete remission was obtained after 1 cycle of inotuzumab ozogamicin therapy. " 08/25/2016 - "The rate of complete remission was higher with inotuzumab ozogamicin than with standard therapy, and a higher percentage of patients in the inotuzumab ozogamicin group had results below the threshold for minimal residual disease. " 09/01/2018 - "Inotuzumab ozogamicin improves response rate, minimal residual disease negativity, and survival compared to standard chemotherapy in this population. " 12/01/2017 - "One recent development is the FDA approved therapy inotuzumab ozogamicin which has the potential to reduce the overall toxicity of intensive regimens for ALL, as well as to possibly increase the number of patients who may achieve a state of minimal residual disease. "
3.	Philadelphia Chromosome 01/01/2018 - "Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study." 10/26/2023 - "Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL." 01/01/2021 - "Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia." 02/01/2018 - "Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial." 06/01/2023 - "Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial."
4.	Non-Hodgkin Lymphoma (Lymphosarcoma) 04/20/2010 - "This was a phase I study to determine the maximum-tolerated dose (MTD), safety, and preliminary efficacy of inotuzumab ozogamicin in an expanded MTD cohort of patients with relapsed or refractory CD22(+) B-cell non-Hodgkin's lymphoma (NHL). " 10/01/2016 - "Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma." 01/01/2019 - "Inotuzumab ozogamicin (1.8 mg m-2 per cycle) is not predicted to pose a clinically significant safety risk for QT prolongation in patients with acute lymphoblastic leukaemia or non-Hodgkin lymphoma." 10/01/2016 - "The aim of this investigation was to develop a quantitative method to optimize inotuzumab ozogamicin (InO) dosage regimen in patients with indolent non-Hodgkin lymphoma (NHL) by simultaneously balancing safety and efficacy. " 01/01/2014 - "Inotuzumab ozogamicin has shown promising single-agent activity in patients with ALL and in CD22 positive non-Hodgkin lymphoma. "
5.	Neoplasms (Cancer) 04/01/2011 - "Here, we describe anti-tumor efficacy of CMC-544, CHOP or CVP against human BCL xenografts. " 01/01/2019 - "The aim of this study was to characterize the effect of inotuzumab ozogamicin on QT interval in patients with B-cell malignancies. " 01/01/2019 - "Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc-concentration modelling." 12/01/2017 - "Inotuzumab ozogamicin binds to CD22-expressing tumor cells, resulting in apoptotic cell death. " 01/01/2016 - "The preclinical model was translated to the clinic by incorporating human PK for inotuzumab ozogamicin and clinically relevant tumor volumes, tumor growth rates, and values for CD22 expression in the relevant patient populations. "

Related Drugs and Biologics

1.	Calicheamicins
2.	blinatumomab
3.	Rituximab (Mabthera)
4.	Immunoconjugates (Immunoconjugate)
5.	Monoclonal Antibodies
6.	Cyclophosphamide (Cytoxan)
7.	Inotuzumab Ozogamicin
8.	Antigens
9.	Vincristine (Oncovin)
10.	Dexamethasone (Maxidex)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Stem Cell Transplantation
4.	Immunotherapy
5.	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation)